Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLOTYN vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Relapsed or refractory peripheral T-cell lymphoma (PTCL)
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Pralatrexate is primarily metabolized via hepatic metabolism; specific enzymes not fully characterized. It is not a significant substrate for CYP450 enzymes.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 67% bound to human plasma proteins, primarily albumin.
Approximately 85-90% bound to serum albumin.
Volume of distribution at steady state is approximately 0.5 L/kg (range 0.3–0.7 L/kg), indicating distribution into total body water with some tissue binding.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Only intravenous administration is approved; oral bioavailability has not been established (not for oral use).
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No specific dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: 2.0 mg/m2. Child-Pugh B: 1.5 mg/m2. Child-Pugh C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Not approved for pediatric use; safety and efficacy not established.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustments; monitor for renal function and toxicity as elderly patients may have reduced organ function.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
WARNING: FOLOTYN may cause severe or fatal mucositis, thrombocytopenia, and other hematologic toxicities. Administer with close monitoring, and manage with dose modifications and supportive care as needed.
None.
Mucositis, hematologic toxicity (including thrombocytopenia, neutropenia, anemia), dermatologic reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), tumor lysis syndrome, hepatotoxicity, and renal toxicity. Monitor complete blood counts, liver function, renal function, and mucositis. Dose adjustments required for toxicity.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to pralatrexate or any component of the formulation.
Hypersensitivity to AURLUMYN or any of its components.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction leading to increased toxicity. No other specific food restrictions.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
FOLOTYN (pralatrexate) is a folate analog metabolic inhibitor; based on its mechanism of action and animal studies, it is expected to cause fetal harm when administered to a pregnant woman. In animal reproduction studies, pralatrexate caused embryo-fetal toxicity and malformations at doses below the recommended human dose. There are no adequate and well-controlled studies in pregnant women. Advise pregnant women of the potential risk to a fetus. During first trimester: high risk of teratogenicity (neural tube defects, cardiovascular malformations). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and fetal death.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No data are available regarding the presence of pralatrexate in human milk, effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with FOLOTYN and for at least 1 week after the last dose. M/P ratio: unknown.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Physiologic changes in pregnancy can alter drug pharmacokinetics, but there are no established dosing guidelines for FOLOTYN during pregnancy. Dose adjustments should be based on toxicity monitoring (e.g., mucositis, myelosuppression). Due to potential for teratogenicity, avoid use in pregnancy unless benefit outweighs risk. No specific dose adjustments recommended for pregnancy alone.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Administer intramuscularly; rotate injection sites. Premedicate with corticosteroid, antihistamine, and antipyretic to reduce infusion reactions. Monitor for tumor lysis syndrome, hepatotoxicity, and myelosuppression. Dose adjustment required for renal impairment (Cr Cl <50 m L/min). Contraindicated in pregnancy.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
This medicine is given as an injection into a muscle, usually once weekly.,You may receive medications before your dose to prevent allergic reactions.,Report any signs of infection, unusual bleeding, or bruising promptly.,Avoid pregnancy during treatment; use effective contraception.,Limit alcohol intake to reduce liver strain.,Avoid grapefruit and grapefruit juice as they may increase side effects.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLOTYN vs AURLUMYN, answered by our medical review team.
FOLOTYN is a Antineoplastic Agent that works by FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLOTYN and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLOTYN is: 3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLOTYN and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLOTYN is classified as Category C. FOLOTYN (pralatrexate) is a folate analog metabolic inhibitor; based on its mechanism of action and animal studies, it is expected to cause fetal harm when administered to a pregna. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.